Federated Hermes
PACB icon

Federated Hermes’s Pacific Biosciences PACB Stock Holding History

Federated Hermes’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-137
Closed -$170 – 2202
2025
Q2 		$170 Sell
137
-465,121
-100% -$537K ﹤0.01% 2048
2025
Q1 		$549K Buy
465,258
+16,960
+4% +$26K ﹤0.01% 1279
2024
Q4 		$820K Buy
448,298
+5,374
+1% +$10.5K ﹤0.01% 1166
2024
Q3 		$753K Sell
442,924
-3,930
-0.9% -$6.46K ﹤0.01% 1219
2024
Q2 		$612K Buy
+446,854
New +$902K ﹤0.01% 1263
2023
Q4 		– Sell
-19
Closed -$159 – 2163
2023
Q3 		$159 Sell
19
-33,518
-100% -$383K ﹤0.01% 2073
2023
Q2 		$446K Buy
33,537
+33,536
+3,353,600% +$408K ﹤0.01% 1410
2023
Q1 		$12 Hold
1
– – ﹤0.01% 2110
2022
Q4 		$8 Hold
1
– – ﹤0.01% 2145
2022
Q3 		$1K Sell
1
-4,608
-100% -$26.4K ﹤0.01% 2069
2022
Q2 		$20K Buy
+4,609
New +$28K ﹤0.01% 1765
2021
Q2 		– Sell
-59,024
Closed -$1.97M – 2296
2021
Q1 		$1.97M Sell
59,024
-420,612
-88% -$14.7M ﹤0.01% 1115
2020
Q4 		$12.4M Buy
479,636
+147,790
+45% +$2.51M 0.03% 585
2020
Q3 		$3.27M Buy
+331,846
New +$1.91M 0.01% 839
2018
Q4 		– Sell
-1,600,000
Closed -$8.66M – 2270
2018
Q3 		$8.66M Buy
+1,600,000
New +$6.87M 0.02% 623
2016
Q3 		– Sell
-576
Closed -$4K – 2153
2016
Q2 		$4K Sell
576
-33
-5% -$301 ﹤0.01% 1925
2016
Q1 		$5K Buy
+609
New +$5.99K ﹤0.01% 1878
2015
Q2 		– Sell
-838
Closed -$5K – 2033
2015
Q1 		$5K Buy
+838
New +$5.78K ﹤0.01% 1869

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

Federated Hermes's PACB Position: Q3 2025 in Review

Federated Hermes sold out of Pacific Biosciences (PACB) in Q3 2025, closing a stake of 137 shares — an estimated $170 sold.

Federated Hermes first reported a position in PACB in Q1 2015 and held it in 18 quarters. The position peaked at $12.4M in Q4 2020. 208 funds tracked by Wall St. Rank hold PACB as of Q3 2025.

  • Federated Hermes reported no remaining Pacific Biosciences position as of Q3 2025 after selling out during the quarter.
  • Federated Hermes sold 137 Pacific Biosciences shares in Q3 2025, an estimated $170.
  • Federated Hermes first reported a position in Pacific Biosciences in Q1 2015 and held it in 18 quarters.
  • Federated Hermes's Pacific Biosciences position peaked at $12.4M in Q4 2020.
  • 208 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2025.

Based on Federated Hermes's 13F filing for Q3 2025, filed 3 Nov 2025.